French specialty vaccine company Valneva (Euronext: VLA) has announced it is in advanced discussions with European authorities to supply up to 60 million doses of its COVID-19 vaccine, VLA2001.
News of the deal saw Valneva's shares up more than 12% at 10.38 euros at midday today.
VLA2001, currently the only inactivated COVID-19 vaccine candidate in European clinical trials, leverages the same manufacturing platform used for the firm’s encephalitis vaccine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze